home icon

right icon

Stocks

right icon

CAPLIPOINT

CAPLIPOINT

CAPLIPOINT

Pharmaceuticals & Drugs

739.8

0.00 (0.00%)

stock change
Market Cap5,618 CrEPS24.9High750.95
Stock P/E29.7Net Profit Margin25.6Low740.05
home icon
The current prices are delayed, login to your account to see live prices.
LOGIN
explain

Caplin Point Labs Price chart

explain

NSE: Caplin Point Labs

explain

Performance

Today’s Low

Today’s High

740.05

750.95

52W Low

52W High

626

888

Open Price739.8Volume1
Prev. Close739.8
explain

Fundamentals

explain
Market Cap5,618 CrROE24.7%
P/E Ratio(TTM)29.7EPS(TTM)41.4
P/B Ratio5.4Dividend Yield0.5%
Industry P/E64.4Book Value137.1
Face Value2.0
explain

About the Company

Caplin Point Laboratories was established in 1990 to manufacture a range of ointments, creams and other external applications. The Company was listed in 1994; the IPO proceeds were deployed in a manufacturing facility in Pondicherry. The promoters exposed their lives to physical risk when they ventured into war-affected countries more than two decades ago. The Company ventured into the emerging markets of West Africa, Latin America and The Caribbean to market finished formulations. The Company’s asset-light marketing business model has helped generate the resources to build world-class infrastructure.

The success of Caplin Point is primarily attributed to its unique business model. Starting of as an SME, Caplin Point decided at an early stage that the conventional style of exports would mean diminishing margins and reduced opportunities for expansion, and had taken the unique step of creating last mile logistical solutions for its exclusive distributors across Latin America and various parts of Africa. This way, Caplin Point is able to generate adequate revenue and cash flow to remain debt-free with benchmark receivables, and also continue to invest in state of the art manufacturing facilities from internal accruals. One of the main reasons for the success can be attributed to the wide range of products offered across diverse geographies.

Business area of the company

Caplin Point is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.

Products

  • Liquid Injections
  • Lyophilised Injections
  • Opthalmic
  • Tablets
  • Liquid Orals
  • Capsule
  • Softgel Capsules
  • Suppositories & Ovules
  • Powder for Injection
  • Dry syrup
  • Topicals
  • Liquid Injections
  • Inhalers
  • Ophthalmic
  • IV Infusion
  • Lyophilised Products
  • Branded Products
  • Dermo Cosmetics

Awards and recognitions

  • 2014: Forbes Asia Best under a Billion Award - 2014.
  • 2015: Forbes Asia Best under a Billion Award - 2015.
  • 2016: Forbes Asia Best under a Billion Award - 2016.
  • 2017: Nanayam Vikatan’s Gold Phoenix Award to Mr. C C Paarthipan.
  • 2017: Financial express CFO Awards 2017 (Second Rank).
  • 2017: IPF’s industrial Excellance Award.
  • 2018: The Economic Times - Family Business of the year Award.
  • 2018: Pharmexcil Outstanding Exports Award 2018.
  • 2018: The Economic Times Award for Excellence in Business Performance.
  • 2019: Empowering India Awards 2019 in Pharmaceutical, Healthcare and Bio-Technology Segment.
Parent OrganisationCaplin Point Laboratories Ltd.Managing DirectorSridhar Ganesan
Founded1990NSE SymbolCAPLIPOINT
explain

Financials

All values are in Rs Cr

explain

Shareholding Pattern

explain

Peer Comparison

Company52 WeekMarket PriceP/E Ratio
SEE MORE
explain

Recently Viewed

No Recently Viewed Stocks
explain

Frequently asked questions

You can buy the shares of Caplin Point Labs using the Trinkerr Website or by downloading the Trinkerr app from Android and Apptore.